{"id":70747,"date":"2026-05-12T10:39:40","date_gmt":"2026-05-12T10:39:40","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70747"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"cagrilintide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/cagrilintide\/","title":{"rendered":"\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 \u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9<\/strong> (developmental code AM833) is a 37-amino-acid long-acting synthetic amylin analog developed by Novo Nordisk. It is the lead amylin-class peptide in current metabolic support and the partner compound in the CagriSema combination (cagrilintide + <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a>), now in late-stage Phase 3 trials for obesity and type 2 diabetes. Plasma half-life ~159 hours enables once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1415456-99-3\uff08\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\uff1b\u4e00\u822c\u7684\u306b\u5f15\u7528\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u30bf\u30a4\u30d7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9577\u6642\u9593\u4f5c\u7528\u578b\u5408\u6210\u30a2\u30df\u30ea\u30f3\u30a2\u30ca\u30ed\u30b0\uff08\u30a2\u30b7\u30eb\u531637\u30a2\u30df\u30ce\u9178\u30da\u30d7\u30c1\u30c9\uff1b\u30ab\u30eb\u30b7\u30c8\u30cb\u30f3\uff0f\u30a2\u30df\u30ea\u30f3\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\uff1b\u30ce\u30dc \u30ce\u30eb\u30c7\u30a3\u30b9\u30af\u958b\u767a\u30b3\u30fc\u30c9 AM833\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u7d044,981 Da\uff08C20\u8102\u80aa\u9178\u4e8c\u9178\u30a2\u30b7\u30eb\u5316\u304a\u3088\u3073\u5206\u5b50\u5185\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u542b\u3080\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u69cb\u9020<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u30d2\u30c8\u30a2\u30df\u30ea\u30f3\u9aa8\u683c\u306b\u57fa\u3065\u304f37\u30a2\u30df\u30ce\u9178\u3067\u3001\u30a2\u30df\u30ed\u30a4\u30c9\u5f62\u6210\u51dd\u96c6\u3092\u6e1b\u5c11\u3055\u305b\u308b\u7f6e\u63db\u3001\u53d7\u5bb9\u4f53\u7d50\u5408\u306b\u5fc5\u8981\u306a\u5206\u5b50\u5185Cys2\u2013Cys7\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3001\u03b3-Glu-OEG-OEG\u30b9\u30da\u30fc\u30b5\u30fc\u3092\u4ecb\u3057\u3066\u7d50\u5408\u3057\u3001\u90311\u56de\u306e\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f\u3092\u5b9f\u73fe\u3059\u308b\u5f37\u529b\u306a\u53ef\u9006\u7684\u8840\u6e05\u30a2\u30eb\u30d6\u30df\u30f3\u7d50\u5408\u3092\u4fc3\u3059C20\u8102\u80aa\u9178\u4e8c\u9178\u30a2\u30b7\u30eb\u9396\u3092\u542b\u307f\u307e\u3059\u3002C\u672b\u7aef\u306f\u30a2\u30df\u30c9\u5316\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\uff08\u767d\u8272\u301c\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u4f7f\u7528\u6642\u5728\u5eab\u306f2\uff5e8\u2103\uff08\u51b7\u8535\uff09\u306b\u4fdd\u7ba1\u3002\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306b\u306f\u221220\u2103\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u2103\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u4f7f\u7528\u671f\u9593\u304c\u77ed\u3044\u5834\u5408\u306f\u6ec5\u83cc\u6c34\u3002\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u3001\u5c0f\u3055\u306a\u4fee\u98fe\u3055\u308c\u3066\u3044\u306a\u3044\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u6eb6\u89e3\u304c\u9045\u3044\u5834\u5408\u304c\u3042\u308a\u307e\u3059\u306e\u3067\u3001\u8ffd\u52a0\u306e\u5e73\u8861\u6642\u9593\u3092\u53d6\u3063\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9<\/strong> is a long-acting synthetic analog of amylin \u2014 a 37-amino-acid pancreatic peptide hormone co-secreted with insulin from beta cells and one of the principal endogenous regulators of postprandial glucose excursion, satiety signalling, and gastric emptying. Endogenous human amylin has a short plasma half-life (~13 minutes), poor pharmacokinetics, and a strong tendency to form amyloid aggregates (the same islet amyloid that accumulates in type 2 diabetic pancreas tissue). Cagrilintide was engineered by Novo Nordisk (developmental code AM833) to overcome each of these limitations: substitutions to reduce aggregation, an intramolecular disulfide bridge preserved for receptor binding, and a C20 fatty-diacid acyl chain attached via a \u03b3-Glu-OEG-OEG spacer that drives strong reversible binding to circulating serum albumin. The combined effect is a plasma half-life of approximately 159 hours (~6.5 days), enabling once-weekly subcutaneous dosing. Cagrilintide has a mature molecular weight of approximately 4,981\u00a0Da including the acyl chain and disulfide bridge. The intramolecular Cys2\u2013Cys7 disulfide is essential for receptor binding \u2014 reduction of this bond converts the peptide into an inactive linear form. The fatty-acid tether is one carbon longer than semaglutide&#8217;s C18 acyl chain, producing the long half-life through the same albumin-binding mechanism. Cagrilintide is the most advanced compound in the renewed wave of amylin-pathway pharmacology, with the lead clinical programme being the <strong>CagriSema\u4f75\u7528\u7642\u6cd5<\/strong> \u2014 \u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9 2.4 mg + <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> 2.4 mg \u90311\u56de \u2014 \u3053\u308c\u306fREDEFINE-1\uff08\u80a5\u6e80\u75c7\uff09\u304a\u3088\u3073REDEFINE-2\uff082\u578b\u7cd6\u5c3f\u75c5\uff09\u7b2c3\u76f8\u8a66\u9a13\u3092\u5b8c\u4e86\u3057\u300168\u9031\u9593\u3067\u7d0420\uff5e23%\u306e\u4f53\u91cd\u6e1b\u5c11\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f <strong>\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a stand-alone agent or in combination. <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 \u4e2d\u67a2\u304a\u3088\u3073\u672b\u68a2\u90e8\u4f4d\u306b\u308f\u305f\u308b\u30a2\u30df\u30ea\u30f3\u53d7\u5bb9\u4f53\u4f5c\u52d5\u4f5c\u7528<\/h2>\n<p>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u304cGLP-1\u4f5c\u52d5\u85ac\u3068\u85ac\u7406\u5b66\u7684\u306b\u7570\u306a\u308b\u70b9\u306f\u3001\u305d\u308c\u304c\u4f5c\u7528\u3059\u308b\u306e\u304c <strong>\u5168\u304f\u7570\u306a\u308b\u53d7\u5bb9\u4f53\u30b7\u30b9\u30c6\u30e0 \u2014 \u30a2\u30df\u30ea\u30f3\/\u30ab\u30eb\u30b7\u30c8\u30cb\u30f3\u53d7\u5bb9\u4f53\u30d5\u30a1\u30df\u30ea\u30fc \u2014 \u3092\u4ecb\u3057\u3066\u30013\u3064\u306e\u4e3b\u8981\u306a\u30e1\u30ab\u30cb\u30ba\u30e0\u3067<\/strong> documented in published studies:<\/p>\n<ul>\n<li><strong>\u30a2\u30df\u30ea\u30f3\u53d7\u5bb9\u4f53\uff08AMY1\u3001AMY2\u3001AMY3\uff09\u4f5c\u52d5\u4f5c\u7528 \u2014 \u8133\u5e79\u6e80\u8179\u56de\u8def<\/strong> \u2014 \u30a2\u30df\u30ea\u30f3\u53d7\u5bb9\u4f53\u306f\u3001\u30ab\u30eb\u30b7\u30c8\u30cb\u30f3\u53d7\u5bb9\u4f53\uff08CTR\uff09\u3068\u53d7\u5bb9\u4f53\u6d3b\u6027\u4fee\u98fe\u30bf\u30f3\u30d1\u30af\u8ceaRAMP1\u3001RAMP2\u3001RAMP3\u3068\u306e\u30d8\u30c6\u30ed\u4e8c\u91cf\u4f53\u3067\u3042\u308a\u3001AMY1\u3001AMY2\u3001AMY3\u53d7\u5bb9\u4f53\u30b5\u30d6\u30bf\u30a4\u30d7\u3092\u751f\u6210\u3057\u307e\u3059\u3002\u6e80\u8179\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u306e\u4e3b\u306a\u4f5c\u7528\u90e8\u4f4d\u306f\u8133\u5e79\u306e\u6700\u5f8c\u91ce\uff08area postrema\uff09\u3067\u3042\u308a\u3001\u3053\u308c\u306f\u8840\u6db2\u8133\u95a2\u9580\u3092\u6301\u305f\u306a\u3044\u6570\u5c11\u306a\u3044\u4e2d\u67a2\u795e\u7d4c\u7cfb\u9818\u57df\u306e\u4e00\u3064\u3067\u3001\u5faa\u74b0\u30a2\u30df\u30ea\u30f3\u3084\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306e\u3088\u3046\u306a\u30a2\u30b7\u30eb\u5316\u30a2\u30ca\u30ed\u30b0\u304c\u76f4\u63a5\u30a2\u30af\u30bb\u30b9\u3067\u304d\u307e\u3059\u3002\u8133\u5e79AMY\u53d7\u5bb9\u4f53\u306e\u6d3b\u6027\u5316\u306f\u3001\u8ff7\u8d70\u795e\u7d4c\u304a\u3088\u3073\u30ce\u30eb\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u4f5c\u52d5\u6027\u6295\u5c04\u3092\u8996\u5e8a\u4e0b\u90e8\u306b\u5f15\u304d\u8d77\u3053\u3057\u3001\u98df\u4e8b\u3054\u3068\u306e\u30bf\u30a4\u30e0\u30b9\u30b1\u30fc\u30eb\u3067\u98df\u7269\u6442\u53d6\u3092\u6291\u5236\u3057\u307e\u3059\u3002<\/li>\n<li><strong>\u30b0\u30eb\u30ab\u30b4\u30f3\u5206\u6ccc\u6291\u5236\u3068\u80c3\u5185\u5bb9\u6392\u51fa\u9045\u5ef6<\/strong> \u2014 \u4e2d\u67a2\u6027\u306e\u6e80\u8179\u611f\u306b\u52a0\u3048\u3066\u3001\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u30a2\u30df\u30ea\u30f3\u306e\u672b\u68a2\u4ee3\u8b1d\u4f5c\u7528\u3092\u518d\u73fe\u3057\u307e\u3059\uff1a\u81b5\u03b1\u7d30\u80de\u304b\u3089\u306e\u30b0\u30eb\u30b3\u30fc\u30b9\u4f9d\u5b58\u6027\u30b0\u30eb\u30ab\u30b4\u30f3\u5206\u6ccc\u6291\u5236\u3001\u98df\u5f8c\u306e\u809d\u81d3\u30b0\u30eb\u30b3\u30fc\u30b9\u653e\u51fa\u306e\u6e1b\u5c11\u3001\u305d\u3057\u3066\u9855\u8457\u306a\u80c3\u5185\u5bb9\u6392\u51fa\u9045\u5ef6\u3067\u3059\u3002\u80c3\u5185\u5bb9\u6392\u51fa\u9045\u5ef6\u306f\u98df\u5f8c\u306e\u6e80\u8179\u30b7\u30b0\u30ca\u30eb\u3092\u5ef6\u9577\u3059\u308b\u3053\u3068\u3067\u6e80\u8179\u611f\u3092\u5f37\u5316\u3057\u3001\u98df\u5f8c\u8840\u7cd6\u4e0a\u6607\u306e\u7a0b\u5ea6\u3092\u8efd\u6e1b\u3057\u307e\u3059\u3002\u80c3\u5185\u5bb9\u6392\u51fa\u9045\u5ef6\u306e\u30bf\u30ad\u30d5\u30a3\u30e9\u30ad\u30b7\u30b9\uff08\u90e8\u5206\u7684\u306a\u8131\u611f\u4f5c\uff09\u306f\u3001\u53d7\u5bb9\u4f53\u306e\u6301\u7d9a\u7684\u5360\u6709\u304c\u7d9a\u304f\u6570\u9031\u9593\u306b\u308f\u305f\u3063\u3066\u767a\u751f\u3057\u3001GLP-1\u7cfb\u306e\u30d1\u30bf\u30fc\u30f3\u3068\u4e26\u884c\u3057\u3066\u3044\u307e\u3059\u3002<\/li>\n<li><strong>GLP-1\u3078\u306e\u88dc\u5b8c\u7684\u30e1\u30ab\u30cb\u30ba\u30e0 \u2014 CagriSema\u306e\u7406\u8ad6\u7684\u6839\u62e0<\/strong> \u2014 \u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u3092\u4f75\u7528\u3059\u308b\u81e8\u5e8a\u7684\u6839\u62e0 <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> \u975e\u91cd\u8907\u7684\u306a\u30e1\u30ab\u30cb\u30ba\u30e0\u306b\u57fa\u3065\u3044\u3066\u3044\u307e\u3059\u3002GLP-1\u4f5c\u52d5\u85ac\u306f\u4e3b\u306b\u8996\u5e8a\u4e0b\u90e8\u5f13\u72b6\u6838\u306ePOMC\u30cb\u30e5\u30fc\u30ed\u30f3\uff08\u4e2d\u67a2\u98df\u6b32\u7cfb\u3092\u4ecb\u3057\u305f\u98df\u7269\u6442\u53d6\u8abf\u7bc0\uff09\u304a\u3088\u3073\u81b5\u03b2\u7d30\u80de\uff08\u30b0\u30eb\u30b3\u30fc\u30b9\u4f9d\u5b58\u6027\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\uff09\u306b\u4f5c\u7528\u3057\u307e\u3059\u3002\u30a2\u30df\u30ea\u30f3\u4f5c\u52d5\u85ac\u306f\u4e3b\u306b\u8133\u5e79\u6700\u5f8c\u91ce\u306eAMY\u53d7\u5bb9\u4f53\uff08\u98df\u4e8b\u3054\u3068\u306e\u6e80\u8179\u611f\u5f37\u5316\uff09\u304a\u3088\u3073\u81b5\u03b1\u7d30\u80de\uff08\u30b0\u30eb\u30ab\u30b4\u30f3\u5206\u6ccc\u6291\u5236\uff09\u306b\u4f5c\u7528\u3057\u307e\u3059\u3002\u3053\u306e2\u3064\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u306f\u91cd\u8907\u3067\u306f\u306a\u304f\u6a5f\u69cb\u7684\u306b\u76f8\u52a0\u7684\u3067\u3042\u308a\u3001\u305d\u308c\u3086\u3048\u306bCagriSema\u306f\u7b2c3\u76f8\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9<\/a> GIP\u307e\u305f\u306f\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u3092\u4ecb\u3055\u305a\u306b\u3002<\/li>\n<\/ul>\n<p>The C20 fatty-diacid acylation at lysine (analogous to semaglutide&#8217;s C18 modification) drives reversible serum-albumin binding that produces the ~159-hour plasma half-life. The intramolecular Cys2\u2013Cys7 disulfide bridge maintains the bioactive conformation required for AMY-receptor binding \u2014 users must avoid vigorous shaking or freeze-thaw cycles that could disrupt the disulfide. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Cagrilintide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>\u80a5\u6e80\u3068\u4f53\u91cd\u8abf\u7bc0<\/strong> \u2014 preclinical DIO (diet-induced obesity) rodent models, body-composition (DEXA\/MRI), food-intake assays, energy-expenditure characterisation; canonical peptide for the renewed amylin-pathway pharmacology programme<\/li>\n<li><strong>Combined cagrilintide + GLP-1 (CagriSema) studies<\/strong> \u2014 \u76f4\u63a5\u6bd4\u8f03\u8a66\u9a13\u304a\u3088\u3073\u4f75\u7528\u8a66\u9a13\u3092\u5b9f\u65bd <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> \u80a5\u6e80\u30e2\u30c7\u30eb\u304a\u3088\u30732\u578b\u7cd6\u5c3f\u75c5\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\uff1b\u76f8\u88dc\u7684\u3001\u76f8\u52a0\u7684\u3001\u76f8\u4e57\u7684\u306a\u4f53\u91cd\u6e1b\u5c11\u52b9\u679c\u306e\u6a5f\u5e8f\u89e3\u6790\uff08Enebo et al., Lancet 2021; CagriSema\u7b2c3\u76f8\u8a66\u9a13\u7d50\u679c\uff09<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 \u9ad8\u8102\u80aa\u98df\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u3001\u98df\u5f8c\u8840\u7cd6\u5909\u52d5<\/li>\n<li><strong>\u30a2\u30df\u30ea\u30f3\u53d7\u5bb9\u4f53\u85ac\u7406<\/strong> \u2014 AMY1\/AMY2\/AMY3\u53d7\u5bb9\u4f53\u30b5\u30d6\u30bf\u30a4\u30d7\u9078\u629e\u6027\u3001RAMP\u4f9d\u5b58\u6027\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3001\u30ab\u30eb\u30b7\u30c8\u30cb\u30f3\u53d7\u5bb9\u4f53\u3068\u30a2\u30df\u30ea\u30f3\u53d7\u5bb9\u4f53\u306b\u304a\u3051\u308b\u30a2\u30b4\u30cb\u30b9\u30c8\u52b9\u529b\u306e\u6bd4\u8f03<\/li>\n<li><strong>Brainstem satiety-circuit studies<\/strong> \u2014 \u6700\u5f8c\u91ce\u7279\u7570\u7684\u53d7\u5bb9\u4f53\u6d3b\u6027\u5316\u3001\u8ff7\u8d70\u795e\u7d4c\u304a\u3088\u3073\u30ce\u30eb\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u4f5c\u52d5\u6027\u6295\u5c04\u30de\u30c3\u30d4\u30f3\u30b0\u3001\u5f13\u72b6\u6838GLP-1\u6a5f\u69cb\u3068\u306e\u533a\u5225<\/li>\n<li><strong>Gastric emptying and postprandial physiology studies<\/strong> \u2014 \u80c3\u6392\u51fa\u6642\u9593\u3001\u98df\u5f8c\u8840\u7cd6\u52d5\u614b\u3001\u8178\u7ba1\u30db\u30eb\u30e2\u30f3\u8ef8\u306e\u7d71\u5408<\/li>\n<li><strong>Comparative incretin\/amylin peptide studies<\/strong> \u2014 GLP-1\u5358\u72ec\u4f5c\u52d5\u85ac\u3068\u306e\u6bd4\u8f03\uff08<a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a>\uff09\u3001GIP\/GLP-1\u4e8c\u91cd\u4f5c\u52d5\u85ac\uff08<a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a>\uff09\u3001\u306a\u3089\u3073\u306b\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8GLP-1\/GIP\/\u30b0\u30eb\u30ab\u30b4\u30f3\uff08<a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a>\uff09\u4f53\u91cd\u52b9\u679c\u3001\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3001\u304a\u3088\u3073\u526f\u4f5c\u7528\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306b\u3064\u3044\u3066\u3002<\/li>\n<\/ul>\n<p>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u304c\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u306e\u5168\u4f53\u50cf\u306b\u304a\u3044\u3066\u3069\u306e\u3088\u3046\u306a\u4f4d\u7f6e\u3065\u3051\u306b\u3042\u308b\u304b\u306b\u3064\u3044\u3066\u306e\u3088\u308a\u5e83\u3044\u80cc\u666f\u306b\u3064\u3044\u3066\u306f\u3001\u3053\u3061\u3089\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002 <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> CagriSema\u306e\u4f75\u7528\u30d1\u30fc\u30c8\u30ca\u30fc\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a> \u4e8c\u91cd\u53d7\u5bb9\u4f53\u6bd4\u8f03\u5bfe\u7167\u85ac\u3068\u3057\u3066\u3001\u306a\u3089\u3073\u306b <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> \u4e09\u91cd\u53d7\u5bb9\u4f53\u6bd4\u8f03\u5bfe\u7167\u85ac\u3068\u3057\u3066\u3002\u5168 <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks Cagrilintide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, short-cycle titration studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u9577\u671f\u30b5\u30a4\u30af\u30eb\u30d7\u30ed\u30c8\u30b3\u30eb\u3001\u591a\u30b3\u30db\u30fc\u30c8\u7814\u7a76\u30011mg\u3042\u305f\u308a\u6700\u5b89\u30b3\u30b9\u30c8<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 2.4\u00a0mg weekly (the CagriSema arm), so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Cagrilintide is a comparatively scarce peptide because of the structural complexity (disulfide bridge + acyl tether) and ongoing clinical development controls, which is reflected in the per-mg price relative to small synthetic peptides. <\/p>\n<h2>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u3068\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306e\u6bd4\u8f03<\/h2>\n<p>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u3068 <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> CagriSema\u914d\u5408\u5264\u306e2\u3064\u306e\u69cb\u6210\u6210\u5206\u3067\u3042\u308a\u3001\u73fe\u5728\u306e\u80a5\u6e80\u85ac\u7406\u5b66\u306b\u304a\u3051\u308b\u30d5\u30a7\u30fc\u30ba3\u81e8\u5e8a\u8a66\u9a13\u306e\u4e2d\u6838\u7684\u5316\u5408\u7269\u3067\u3059\u3002\u4e21\u6210\u5206\u306f\u5168\u304f\u7570\u306a\u308b\u53d7\u5bb9\u4f53\u30b7\u30b9\u30c6\u30e0\uff08\u30a2\u30df\u30ea\u30f3\uff0f\u30ab\u30eb\u30b7\u30c8\u30cb\u30f3\u7cfb \u5bfe GLP-1\u7cfb\uff09\u306b\u4f5c\u7528\u3057\u3001\u6a5f\u5e8f\u7684\u306b\u76f8\u88dc\u7684\u306a\u52b9\u679c\u3092\u3082\u305f\u3089\u3057\u307e\u3059\u3002\u4e00\u65b9\u3067\u306f\u30a2\u30df\u30ea\u30f3\u7d4c\u8def\u306b\u3088\u308b\u6e80\u8179\u611f\u306e\u5f37\u5316\u3068\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u3001\u4ed6\u65b9\u3067\u306fGLP-1\u7d4c\u8def\u306b\u3088\u308b\u98df\u6b32\u8abf\u7bc0\u3068\u30b0\u30eb\u30b3\u30fc\u30b9\u4f9d\u5b58\u6027\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u304c\u5f97\u3089\u308c\u307e\u3059\u3002 <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53d7\u5bb9\u4f53\u30d5\u30a1\u30df\u30ea\u30fc<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30a2\u30df\u30ea\u30f3\uff0f\u30ab\u30eb\u30b7\u30c8\u30cb\u30f3\u53d7\u5bb9\u4f53\u30d5\u30a1\u30df\u30ea\u30fc\uff08AMY1\/2\/3\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1\u53d7\u5bb9\u4f53\uff08GLP-1R\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a2\u30df\u30ce\u9178\u6570<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">37\u30a2\u30df\u30ce\u9178<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">31\u30a2\u30df\u30ce\u9178<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e3b\u306a\u4e2d\u67a2\u795e\u7d4c\u7cfb\u6a19\u7684<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u8133\u5e79\u306e\u6700\u5f8c\u91ce<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u8996\u5e8a\u4e0b\u90e8\u5f13\u72b6\u6838\uff08POMC\u30cb\u30e5\u30fc\u30ed\u30f3\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u672b\u68a2\u4f5c\u7528<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u3001\u80c3\u6392\u51fa\u9045\u5ef6<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u3001\u80c3\u6392\u51fa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8102\u80aa\u9178\u30c6\u30b6\u30fc<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20\u30b8\u30ab\u30eb\u30dc\u30f3\u9178\uff0b\u03b3Glu-OEG-OEG<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C18\u30b8\u30ab\u30eb\u30dc\u30f3\u9178\uff0b\u03b3Glu-AEEA-AEEA<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u534a\u6e1b\u671f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~159\u6642\u9593\uff08~6.5\u65e5\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d04165\u6642\u9593\uff08\u7d047\u65e5\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53c2\u7167\u30d6\u30e9\u30f3\u30c9<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u6cbb\u9a13\u6bb5\u968e (AM833; CagriSema \u4f75\u7528)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4f53\u91cd\u3078\u306e\u52b9\u679c\uff08\u5358\u72ec\u6295\u4e0e\uff09<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0410%\uff08\u7b2c2\u76f8\u5358\u72ec\u6295\u4e0e\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0415%\uff08STEP\u8a66\u9a13\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4f75\u7528\uff08CagriSema\uff09<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\" colspan=\"2\">\u7d0420\uff5e23%\u306e\u4f53\u91cd\u6e1b\u5c11\uff082.4mg + 2.4mg \u90311\u56de\u6295\u4e0e\u3001REDEFINE-1 \u7b2c3\u76f8\u8a66\u9a13\uff09<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in the amylin axis specifically, cagrilintide is the canonical long-acting peptide. For studies interested in maximal body-weight effect via combination pharmacology, the CagriSema model (cagrilintide + <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a>) \u304c\u4e3b\u8981\u306a\u53c2\u7167\u30e2\u30c7\u30eb\u3067\u3059\u3002\u5358\u4e00\u5206\u5b50\u30de\u30eb\u30c1\u30a2\u30b4\u30cb\u30b9\u30c8\u304c\u53d6\u308b\u53d7\u5bb9\u4f53\u30b9\u30bf\u30c3\u30ad\u30f3\u30b0\u30a2\u30d7\u30ed\u30fc\u30c1\u3068\u306e\u6bd4\u8f03\u306b\u3064\u3044\u3066\u306f\u3001 <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a> \uff08\u30c7\u30e5\u30a2\u30ebGLP-1\/GIP\uff09\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> \uff08\u30c8\u30ea\u30d7\u30ebGLP-1\/GIP\/\u30b0\u30eb\u30ab\u30b4\u30f3\uff09\u3092\u3054\u53c2\u7167\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u3001\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u3001\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u7ba1\u306b\u306f\u3001-20\u00b0C\u3067\u51b7\u51cd\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u3001\u51b7\u8535\u3067\u6700\u592724\u30f6\u6708\u3001-20\u00b0C\u3067\u6700\u592736\u30f6\u6708\u9593\u5b89\u5b9a\u3067\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306b\u5bfe\u3057\u3066\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u3092\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002\u4ed6\u306e\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u67b6\u6a4b\u30da\u30d7\u30c1\u30c9\u3068\u540c\u69d8\u306b\u3001\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306e\u53d7\u5bb9\u4f53\u7d50\u5408\u306f\u7121\u50b7\u306eCys2-Cys7\u7d50\u5408\u306b\u4f9d\u5b58\u3057\u3066\u304a\u308a\u3001\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u7834\u58ca\u3059\u308b\u53d6\u308a\u6271\u3044\u306f\u6d3b\u6027\u3092\u4f4e\u4e0b\u3055\u305b\u307e\u3059\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.1\u00a0mL delivers 250\u00a0mcg; ~1.0\u00a0mL delivers a clinical-equivalent 2.4\u00a0mg dose. Swirl gently \u2014 do <strong>\u3057\u307e\u305b\u3093<\/strong> \u632f\u3063\u3066\u304f\u3060\u3055\u3044 \u2014 \u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\u301c10\u5206\u9593\u9759\u7f6e\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u3001\u5c0f\u3055\u306a\u672a\u4fee\u98fe\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u3086\u3063\u304f\u308a\u3068\u6eb6\u3051\u307e\u3059\u3002\u3053\u306e\u5de5\u7a0b\u3092\u6025\u304c\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u6eb6\u89e3\u3055\u308c\u305f\u6eb6\u6db2\u306f\u3001\u900f\u660e\u3067\u7121\u8272\u3067\u3042\u308a\u3001\u76ee\u306b\u898b\u3048\u308b\u7c92\u5b50\u304c\u306a\u3044\u306f\u305a\u3067\u3059\u3002 <strong>\u5b8c\u5168\u306b\u518d\u6eb6\u89e3\u3057\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3042\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/strong> \u632f\u3089\u306a\u3044\u3067\u304f\u3060\u3055\u3044 \u2014 \u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u9759\u7f6e\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u5c0f\u3055\u306a\u672a\u4fee\u98fe\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u6eb6\u89e3\u306b\u6642\u9593\u304c\u304b\u304b\u308a\u307e\u3059\u306e\u3067\u3001\u3053\u306e\u5de5\u7a0b\u3092\u6025\u304c\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u7121\u8272\u900f\u660e\u3067\u3001\u76ee\u306b\u898b\u3048\u308b\u7c92\u5b50\u304c\u306a\u3044\u72b6\u614b\u3067\u306a\u3051\u308c\u3070\u306a\u308a\u307e\u305b\u3093\u3002 <\/p>\n<h2 id=\"faqs\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>What is Cagrilintide used for in studies?<\/h3>\n<p>Cagrilintide is used in studies investigating the amylin\/calcitonin receptor axis, brainstem area-postrema satiety circuits, postprandial glucose physiology, gastric emptying, obesity and body-weight regulation, type 2 diabetes preclinical models, and especially combination pharmacology with GLP-1 agonists (the CagriSema study model with <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a>). It is the most-cited long-acting amylin analog in current metabolic-peptide studies. The pharmaceutical-grade cagrilintide sold here is <strong>\u3057\u307e\u305b\u3093<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>CagriSema\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>CagriSema\u306f\u3001\u56fa\u5b9a\u7528\u91cf\u914d\u5408\u306e\u958b\u767a\u540d\u3067\u3001 <strong>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\uff0b\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/strong> \u90311\u56de2.4mg\uff0b2.4mg\u3067\u3002\u3053\u308c\u306f\u30ce\u30dc \u30ce\u30eb\u30c7\u30a3\u30b9\u30af\u306e\u4e3b\u8981\u306a\u7b2c3\u76f8\u80a5\u6e80\u75c7\u30d7\u30ed\u30b0\u30e9\u30e0\u3067\u3042\u308a\u3001REDEFINE-1\u8a66\u9a13\u304a\u3088\u3073REDEFINE-2\u8a66\u9a13\u3067\u306f\u300168\u9031\u9593\u3067\u7d0420\uff5e23%\u306e\u4f53\u91cd\u6e1b\u5c11\u304c\u5831\u544a\u3055\u308c\u3001CagriSema\u306f\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u3068\u540c\u7a0b\u5ea6\u306e\u52b9\u679c\u30b5\u30a4\u30ba\u7bc4\u56f2\u306b\u4f4d\u7f6e\u3065\u3051\u3089\u308c\u3066\u3044\u307e\u3059 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9<\/a> \u4e00\u65b9\u3067\u3001\u5168\u304f\u7570\u306a\u308b\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u7d4c\u8def\u3092\u3068\u3063\u3066\u3044\u307e\u3059\uff08\u5358\u4e00\u306e\u591a\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\u3067\u306f\u306a\u304f\u30012\u3064\u306e\u5358\u4e00\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\u306e\u7d44\u307f\u5408\u308f\u305b\uff09\u3002\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u3001\u3053\u306e\u7d44\u307f\u5408\u308f\u305b\u306e\u30a2\u30df\u30ea\u30f3\u90e8\u5206\u3067\u3059\u3002 <\/p>\n<h3>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u6839\u672c\u7684\u306a\u9055\u3044\u306f\u53d7\u5bb9\u4f53\u30b7\u30b9\u30c6\u30e0\u3067\u3059\u3002\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u30a2\u30df\u30ea\u30f3\/\u30ab\u30eb\u30b7\u30c8\u30cb\u30f3\u53d7\u5bb9\u4f53\u30d5\u30a1\u30df\u30ea\u30fc\uff08AMY1\u3001AMY2\u3001AMY3\uff09\u306b\u4f5c\u7528\u3057\u3001\u4e3b\u306b\u8133\u5e79\u306e\u6700\u5f8c\u91ce\u3067\u4e2d\u67a2\u4f5c\u7528\u3092\u767a\u63ee\u3057\u307e\u3059\u3002\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306fGLP-1\u53d7\u5bb9\u4f53\u306b\u4f5c\u7528\u3057\u3001\u4e3b\u306b\u8996\u5e8a\u4e0b\u90e8\u306e\u5f13\u72b6\u6838\u3067\u4e2d\u67a2\u4f5c\u7528\u3092\u767a\u63ee\u3057\u307e\u3059\u3002\u3053\u306e2\u3064\u306f\u85ac\u7406\u5b66\u7684\u306b\u76f8\u88dc\u7684\u3067\u3042\u308a\u3001\u7af6\u5408\u3059\u308b\u3082\u306e\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002CagriSema\u306b\u304a\u3051\u308b\u3053\u308c\u3089\u306e\u7d44\u307f\u5408\u308f\u305b\u306f\u3001\u5358\u72ec\u306e\u5834\u5408\u3088\u308a\u3082\u76f8\u52a0\u7684\u306a\u4f53\u91cd\u6e1b\u5c11\u52b9\u679c\u3092\u3082\u305f\u3089\u3057\u307e\u3059\u3002\u3069\u3061\u3089\u3082C20\/C18\u8102\u80aa\u9178\u30a2\u30b7\u30eb\u5316\u306b\u3088\u308b\u9577\u6642\u9593\u4f5c\u7528\u578b\u30da\u30d7\u30c1\u30c9\u3067\u3001\u90311\u56de\u306e\u6295\u4e0e\u304c\u53ef\u80fd\u3067\u3059\u3002 <\/p>\n<h3>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>Tirzepatide is a single molecule that activates two receptors (dual GLP-1\/GIP agonist). Cagrilintide activates only the amylin\/calcitonin receptor family. For studies interested in body-weight magnitude beyond single-receptor GLP-1, tirzepatide takes the \u201creceptor-stacking in one molecule\u201d approach while CagriSema (cagrilintide + semaglutide) takes the \u201cseparate molecules in combination\u201d approach. The two strategies have produced comparable body-weight effect sizes in their respective Phase 3 trials. <\/p>\n<h3>What is the typical Cagrilintide dose?<\/h3>\n<p>Published preclinical and clinical studies protocols use weekly subcutaneous dosing with a titration schedule starting at 0.16\u00a0mg and increasing through 0.3, 0.6, 1.2, and finally 2.4\u00a0mg maintenance weekly \u2014 the same dose used in the CagriSema combination. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 approximately 1.0\u00a0mL equals a 2.4\u00a0mg clinical-equivalent dose. <\/p>\n<h3>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306fFDA\u306b\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>No. Cagrilintide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as either a stand-alone agent or in the CagriSema combination. CagriSema Phase 3 trials (REDEFINE-1 obesity, REDEFINE-2 T2DM) have reported positive results but regulatory submission and review remain ongoing as of current literature. <\/p>\n<h3>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u3069\u306e\u3088\u3046\u306b\u4fdd\u7ba1\u3059\u308c\u3070\u3088\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u51cd\u7d50\u4e7e\u71e5\u54c1\u30d0\u30a4\u30a2\u30eb\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\u3067\u51b7\u8535\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f\uff0d20\u00b0C\u3002\u6eb6\u89e3\u5f8c\u6eb6\u6db2\uff1a2\uff5e8\u00b0C\u3067\u51b7\u8535\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6eb6\u89e3\u5f8c\u6eb6\u6db2\u3092\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u30da\u30d7\u30c1\u30c9\u3092\u5206\u89e3\u3057\u3001\u91cd\u8981\u306aCys2\u2013Cys7\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u7834\u58ca\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u5e38\u306b\u76f4\u5c04\u5149\u3092\u907f\u3051\u3066\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h3>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u3092\u6eb6\u89e3\u3059\u308b\u306b\u306f\u3069\u3046\u3059\u308c\u3070\u3088\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u4e0a\u8a18\u306e\u6eb6\u89e3\u624b\u9806\u306b\u5f93\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u3092\u4f1d\u308f\u305b\u3066\u9759\u83cc\u6c34\u3092\u52a0\u3048\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\uff09\u3001\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3001\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u9759\u7f6e\u3057\u307e\u3059\uff08\u30a2\u30b7\u30eb\u5316\u30da\u30d7\u30c1\u30c9\u306f\u5c0f\u3055\u306a\u672a\u4fee\u98fe\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u6eb6\u89e3\u306b\u6642\u9593\u304c\u304b\u304b\u308a\u307e\u3059\uff09\u3002\u3057 <strong>\u3057\u307e\u305b\u3093<\/strong> \u30d0\u30a4\u30a2\u30eb\u3092\u632f\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u6eb6\u89e3\u3055\u308c\u305f\u6eb6\u6db2\u306f\u900f\u660e\u7121\u8272\u3067\u3001\u76ee\u306b\u898b\u3048\u308b\u7c92\u5b50\u306f\u3042\u308a\u307e\u305b\u3093\u30025 mg \u30d0\u30a4\u30a2\u30eb\uff0b2.0 mL\u6eb6\u89e3\u6db2\u306e\u5834\u5408\u3001\u4f5c\u696d\u6fc3\u5ea6\u306f2.5 mg\/mL\u3067\u3059\u3002 <\/p>\n<h3>MedsBase\u3067\u306f\u3069\u306e\u5bb9\u91cf\u306e\u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9\u3092\u53d6\u308a\u63c3\u3048\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>MedsBase carries Cagrilintide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u306a\u305c\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u4ed6\u306e\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u9ad8\u4fa1\u306a\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>Cagrilintide is structurally complex (37 amino acids with an intramolecular disulfide bridge and a fatty-diacid acyl chain) and is a relatively recent compound still under active clinical development by Novo Nordisk. Both factors contribute to higher synthesis cost and constrained supply relative to mature small synthetic peptides like BPC-157 or TB-500. The per-mg price reflects these supply-and-complexity factors rather than any difference in studies utility. <\/p>\n<h3>Can Cagrilintide be paired with Semaglutide in studies?<\/h3>\n<p>Yes \u2014 this is the canonical CagriSema protocol and the lead Phase 3 clinical combination. Cagrilintide and semaglutide act on different receptor families (amylin\/calcitonin vs GLP-1) with non-overlapping central and peripheral mechanisms, producing additive body-weight effects substantially greater than either alone. The clinical fixed-dose ratio is 2.4\u00a0mg cagrilintide + 2.4\u00a0mg semaglutide weekly. <\/p>\n<h3>Does Cagrilintide cause side reported effects?<\/h3>\n<p>Like other satiety-axis peptides, the most consistent finding is gastrointestinal \u2014 nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4\u20138 weeks of continuous dosing as receptor tachyphylaxis develops. Because cagrilintide is the amylin analog and not a GLP-1, the gastrointestinal profile differs from semaglutide in pattern, but the magnitude is comparable in published clinical studies. Long-term safety data continues to accumulate from Phase 3 trials. <\/p>\n<h3>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306e\u534a\u6e1b\u671f\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>Cagrilintide has a plasma half-life of approximately 159 hours (~6.5 days) following subcutaneous administration. The extended half-life is achieved by reversible binding to circulating serum albumin via the C20 fatty-diacid tether at lysine, which protects the peptide from renal clearance. The half-life is comparable to semaglutide&#8217;s ~165 hours, allowing both compounds to be co-dosed weekly in CagriSema studies without divergent pharmacokinetics. <\/p>\n<h3>How long does Cagrilintide take to show effects in preclinical studies?<\/h3>\n<p>\u6025\u6027\u306e\u85ac\u529b\u5b66\u7684\u52b9\u679c\uff08\u80c3\u6392\u51fa\u30841\u98df\u3054\u3068\u306e\u6e80\u8179\u611f\u306b\u5bfe\u3059\u308b\uff09\u306f\u521d\u56de\u6295\u4e0e\u5f8c\u6570\u6642\u9593\u4ee5\u5185\u306b\u691c\u51fa\u53ef\u80fd\u3067\u3059\u3002DIO\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u4f53\u91cd\u3078\u306e\u52b9\u679c\u306f\u3001\u90311\u56de\u6295\u4e0e\u306e1\uff5e2\u9031\u9593\u5f8c\u306b\u7d71\u8a08\u7684\u306b\u6709\u610f\u3068\u306a\u308a\u30018\uff5e12\u9031\u9593\u307e\u3067\u84c4\u7a4d\u3057\u7d9a\u3051\u307e\u3059\u3002\u4f53\u7d44\u6210\u306b\u5bfe\u3059\u308b\u6700\u5927\u52b9\u679c\u306f16\uff5e24\u9031\u9593\u306e\u9023\u7d9a\u6295\u4e0e\u3067\u5f97\u3089\u308c\u3001\u3053\u308c\u306f\u30d2\u30c8\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2c3\u76f8\u8a66\u9a13REDEFINE-1\u306e\u63a8\u79fb\u3068\u4e00\u81f4\u3057\u307e\u3059\u3002 <\/p>\n<h3>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u306f\u56fd\u969b\u914d\u9001\u3067\u6ce8\u6587\u3067\u304d\u307e\u3059\u304b\uff1f<\/h3>\n<p>Yes. MedsBase ships Cagrilintide worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\">\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Satiety-Axis Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/semaglutide\/\"><strong>\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/strong><\/a> \u2014 Single GLP-1 agonist \u2014 CagriSema combination partner; canonical glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/ja\/tirzepatide\/\"><strong>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/strong><\/a> \u2014 \u30c7\u30e5\u30a2\u30ebGLP-1\/GIP\u30a2\u30b4\u30cb\u30b9\u30c8 \u2014 \u540c\u4e00\u5206\u5b50\u5185\u3067\u306e\u53d7\u5bb9\u4f53\u30b9\u30bf\u30c3\u30ad\u30f3\u30b0\u30b3\u30f3\u30d1\u30ec\u30fc\u30bf<\/li>\n<li><a href=\"\/ja\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 multi-axis metabolic support<\/li>\n<li><a href=\"\/ja\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/ja\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adiposity<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>\u53c2\u8003\u6587\u732e<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 \u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u306e\u4f75\u7528\u30e9\u30f3\u30c9\u30b9\u30b1\u30fc\u30d7\u3092\u63a2\u308b<\/strong><\/p>\n<p style=\"margin: 0;\">\u3059\u3079\u3066\u3092\u95b2\u89a7 <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\"><strong>\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/strong><\/a>, \u3001\u95a2\u9023\u3059\u308b\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u3080 <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> (CagriSema\u4f75\u7528\u85ac), <a href=\"https:\/\/medsbase.com\/ja\/tirzepatide\/\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/a> (\u30c7\u30e5\u30a2\u30ebGLP-1\/GIP\u6bd4\u8f03\u85ac)\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> (\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u6bd4\u8f03\u85ac)\u3002\u76f4\u63a5\u6bd4\u8f03\u30ac\u30a4\u30c9\uff1a <a href=\"https:\/\/medsbase.com\/ja\/retatrutide-vs-tirzepatide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9 vs \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9 \u2014 \u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8 vs \u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705\u9577\u6642\u9593\u4f5c\u7528\u578b\u30a2\u30df\u30ea\u30f3\u985e\u4f3c\u4f53\uff08Novo Nordisk AM833\uff09<br \/>\n\u2705\u30a2\u30df\u30ea\u30f3\uff0f\u30ab\u30eb\u30b7\u30c8\u30cb\u30f3\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac<br \/>\n\u2705\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3068\u306e\u4f75\u7528\u30d1\u30fc\u30c8\u30ca\u30fc\u3001CagriSema<br \/>\n\u2705\u8133\u5e79\u3067\u306e\u6e80\u8179\u611f\u4f5c\u7528\uff0b\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236<br \/>\n\u2705\u90311\u56de\u6295\u4e0e\uff08\u7d04159\u6642\u9593\u306e\u534a\u6e1b\u671f\uff09<\/p>\n<p><strong>\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":70938,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6284,5441],"class_list":["post-70747","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cagrilintide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/70747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=70747"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70938"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=70747"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=70747"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=70747"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=70747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}